IPAC-RS ROUNDTABLES

IPAC-RS has launched a Roundtable webinar series on digital devices for 2021.  Presented by subject matter experts in the pharmaceutical sciences, this is a unique opportunity to learn about the latest research and regulatory trends focused on digital devices.  

The fourth webinar in the series, Business Case for Digital Devices is scheduled for Monday, October 4, 2021 at 10:00 AM - 12:00 PM US ET.   

 

 

Moderators:

  • S. Prasad Peri, Ph.D., Senior Director, Global Specialty Regulatory Affairs, CMC, Teva Branded Pharmaceutical Products R&D Inc.

  • Robyn Parker, MS, Associate Director, Global Regulatory Affairs, Sunovion

 

Speakers:

  • David Pettigrew, DPhil, Vice President Global Accounts, BrightInsight

  • Ulf Ericsson, MS, Vice President Drug Development, Nanologica

Webinar Program and Abstracts:

I.     Welcome and Overview of Webinar

  • Moderators:  Prasad Peri and Robyn Parker

II.    Business Case for Digital Inhaler Devices: A pharma company perspective

  • Ulf Ericsson, Nanologica

 

There are therapy areas that have been exploring the field of digital health for many years and have great solutions in place, a good example is diabetes where some of the solutions have been truly life changing for patients and families as well as providing valuable platforms for the health care systems to manage patients. In Inhaled we are still in a relatively early stage exploring the opportunities and trying to overcome the challenges, that are in many aspects very different to e.g., diabetes. 

 

In inhaled medicine it’s easy to recognize the potential benefits of technical solutions and programs for patients, health care professionals and health care systems, especially given the challenges with adherence to prescribed treatment plans. We will discuss this also from a different stakeholder perspective; for instance, improved adherence is clearly a key value driver both from a clinical outcomes (patient) as well as a business (company) perspective, however from a payer perspective increased adherence is equivalent to increased costs - unless the improved adherence can be translated into significantly improved clinical outcomes. This is one of the challenges we face that will significantly influence the business case (financing model part of it). Thus, the evidence generation is crucial. 

 

What drives a business case in Inhaled digital health? What are the value drivers for a digital solution in Inhaled for different stakeholders? Are there any principles to guide? Trade-offs? What potential business models are there? These are some of the topics we will address in this section. This presentation will introduce a discussion about some guiding principles around business case in digital health in Inhaled respiratory disease management, especially connected inhaler devices.

 

III.    Business Case for Digital Inhaler Devices: A platform provider's perspective on creating a compelling user experience and driving adoption.

  • David Pettigrew, BrightInsight

BrightInsight is a platform provider focusing on delivering medically regulated digital health solutions for Biopharma and Medtech. We are seeing an exciting increase in digital adoption across the patient journey, from diagnosis through to treatment optimization and long-term disease management.

The inhaled drug delivery sector was an early adopter of digital health. Over the last 10 years several connected combination products (and add-on devices) have come to  market, driven primarily by a significant reduction in cost and improved form factors for sensors, Bluetooth LE connectivity and smartphones. However, despite compelling evidence of improved adherence and clinical outcomes, there has been limited uptake of these connected devices in routine clinical practice.

 

In this presentation, we will explore a patient and clinician-centric view of the barriers to adoption and success factors for connected devices, and how they might be addressed. We will discuss how successful digital products are developed to support the uniqueness of each patient - their disease presentation and progression, comorbidities, and quality of life goals. Today, embedding connected device data within a seamless ‘360’ view of the patient is crucial for driving user engagement and adoption. 
 

 

IV.     Moderated Q&A Session with the speakers


Click to view Speaker and Moderator Bios.  Feel free to share the registration information with interested colleagues.